Pneumatic Compression Devices – Community Plan Medical Policy

Coverage Summary

Pneumatic compression devices (PCDs) apply sequential inflation and deflation via garments driven by an air compressor to treat edema and lymphedema, assist wound healing (including chronic venous insufficiency with non-healing lower extremity ulcers), or to prevent deep venous thrombosis (DVT). Devices range from simple intermittent pneumatic compression (IPC) sleeves to more advanced programmable advanced pneumatic compression devices (APCDs) with expanded garment options for specific clinical needs.

This policy (Policy Number CS097.S) defines coverage for intermittent pneumatic compression, pneumatic compression devices, and advanced pneumatic compression systems and references InterQual clinical criteria for specific medical necessity determinations. The policy is effective November 1, 2025.

Medically Necessary Coverage Summary

Pneumatic compression devices are considered medically necessary in certain circumstances for the following:

Lymphedema (general): Treatment of lymphedema (general) in certain circumstances when criteria met per InterQual CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices
Refer to InterQual criteria for medical necessity clinical coverage criteria
Chronic venous insufficiency (CVI): Treatment of chronic venous insufficiency (CVI) with edema and non-healing lower extremity ulcers in certain circumstances when criteria met per InterQual CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices
Refer to InterQual criteria for medical necessity clinical coverage criteria
DVT prevention: Intermittent limb compression devices for prevention of deep venous thrombosis (DVT) in certain circumstances when criteria met per InterQual CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices
Refer to InterQual criteria for medical necessity clinical coverage criteria

HCPCS / Device Codes (informational): Refer to applicable HCPCS codes for device and accessories

See Applicable Codes (e.g., E0650-E0676, A4600) for coding and device descriptions

Clinical findings and guideline-based use

Use and effectiveness of IPC/PCD devices according to evidence and clinical guideline recommendations:

Evidence: DVT prevention in stroke and immobile patients: IPC devices reduce risk of DVT in certain populations (e.g., immobile post-stroke patients) as shown in CLOTS 3 trial: absolute risk reduction 3.6% and adjusted odds ratio 0.65 (95% CI 0.51-0.84).
CLOTS 3 trial results and related HTA findings
Evidence: IPC vs pharmacologic prophylaxis: IPC alone is neither clearly superior nor inferior to pharmacologic prophylaxis in meta-analyses; combined mechanical + pharmacological prophylaxis may further reduce VTE in high-risk patients (Cochrane review).
Systematic reviews and meta-analyses report mixed results and benefit of combined prophylaxis
Evidence: Early post-operative immobilized outpatients: IPC may reduce early DVT after procedures with short-term benefit (e.g., Achilles tendon repair: reduced DVT at 2 weeks but not at 6 weeks).

Not Medically Necessary / Unproven

The following uses are considered unproven and not medically necessary:

APCDs for head/neck lymphedema: Advanced intermittent pneumatic compression devices (APCDs; e.g., Flexitouch) for treating lymphedema of the head, face, or neck
Specifically labeled unproven / not medically necessary; evidence limited and additional research needed
High-pressure devices for PAD: Pneumatic compression devices (high pressure, rapid inflation/deflation cycle) for treating peripheral arterial disease (PAD)
Considered unproven and not medically necessary; evidence inconsistent and insufficient to determine safety/efficacy

Coding note (denial risk): Claims for high-pressure, rapid inflation/deflation pneumatic compression devices (e.g., HCPCS E0675) for treatment of PAD are considered unproven and not medically necessary and are subject to denial.

Coding (HCPCS & Device Codes)

Referenced HCPCS / Procedure Codes (for device and accessories)HCPCS

A4600	Sleeve for intermittent limb compression device, replacement only, each
E0650	Pneumatic compressor, nonsegmental home model
E0651	Pneumatic compressor, segmental home model without calibrated gradient pressure
E0652	Pneumatic compressor, segmental home model with calibrated gradient pressure
E0655	Nonsegmental pneumatic appliance for use with pneumatic compressor, half arm
E0658	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full arms and chest
E0659	Segmental pneumatic appliance for use with pneumatic compressor, integrated, head, neck and chest
E0660	Nonsegmental pneumatic appliance for use with pneumatic compressor, full leg
E0665	Nonsegmental pneumatic appliance for use with pneumatic compressor, full arm
E0666	Nonsegmental pneumatic appliance for use with pneumatic compressor, half leg

1–10 of 19

1/2

Applicable HCPCS / Device Codes (updated)HCPCS

E0658	Intermittent Pneumatic Compression device, not specified elsewhere (added per 11/01/2025)
E0659	Sequential compression device, related supplies (added per 11/01/2025)

FDA product code referencemixed

JOW	FDA product code for pneumatic compression devices (Class II devices)

Provider Actions

Documentation Required

Use InterQual criteria for medical necessity determination

Use InterQual criteria for medical necessity determination. Document the specific InterQual CP used (Durable Medical Equipment, Pneumatic and other Powered Compression Devices) in the medical record. Medical records, including InterQual CP reference and supporting clinical documentation, may be required for review and prior authorization decisions.

Denial Risk

APCDs for head/neck lymphedema: claim denial risk

APCDs for head/neck lymphedema are considered unproven and not medically necessary; claims for these devices are at risk of denial. Document clinical rationale if submitting for review, but expect denial when the primary indication is lymphedema of the head, face, or neck.

Background & Evidence Summary

Pneumatic compression devices use an air compressor connected to a garment (single- or multi-chambered sleeves or more complex garment systems) that sequentially inflate and deflate to apply pressure to the limb or affected area. They are used to reduce edema and treat lymphedema, to assist wound healing such as in chronic venous insufficiency with non-healing lower extremity ulcers, and to prevent DVT by reducing venous stasis and promoting fibrinolytic activity. Device complexity varies from simple IPC sleeves to APCDs with programmability for fibrosis and localized swelling.

The Flexitouch Plus System (an example of an APCD) received FDA clearance on December 20, 2020; FDA clearance information is provided for informational purposes only and is not the sole basis for coverage decisions.

Study/Source	Key finding
Ridner et al. (2021) pilot RCT	APCD (Flexitouch) feasible and safe for head/neck lymphedema with adherence challenges; improvements in perceived control, visible external swelling and pain but small pilot study — supports feasibility and preliminary efficacy; larger RCTs needed.
ECRI 2021 (IPC for PAD)	Assessment found IPC may improve walking distance, wound healing, and rest pain in CLI but included studies had high risk of bias and evidence insufficient for firm conclusions; further RCTs needed.
Alvarez et al. (2020) RCT	IPC plus standard compression reduced median time to venous ulcer closure (141 vs 211 days; p=0.031) and increased healing rate versus compression alone — suggests IPC as valuable adjunct for hard-to-heal venous ulcers.
Cochrane 2022 (Kakkos et al.)	Combined IPC and pharmacologic prophylaxis reduced PE and DVT versus pharmacologic alone (PE OR 0.46; low‑certainty for PE; reduced DVT with higher certainty) — supports combined prophylaxis benefit.
CLOTS 3 trial (Dennis et al./Lancet)	In immobile post-stroke patients IPC reduced DVT: 8.5% vs 12.1% absolute reduction 3.6%; adjusted OR 0.65 (95% CI 0.51-0.84; p=0.001); also improved 6‑month survival (HR 0.86; 95% CI 0.73-0.99; p=0.042).
Domeij‑Arverud et al. (2015) Achilles RCT	In immobilized outpatients after Achilles repair IPC reduced DVT at 2 weeks (21% vs 37%; p=0.042) but no significant difference at 6 weeks after IPC cessation — suggests early benefit that may not persist.
Pavon et al. (2016) systematic review	IPCs comparable to anticoagulation for major clinical outcomes (VTE RR 1.39; 95% CI 0.73-2.64); limited data suggest combining IPC with anticoagulation may lower VTE vs anticoagulation alone — evidence limited and heterogeneous.

Definitions

APCDAdvanced pneumatic compression device with complex garment options and programmability (example: Flexitouch)

IPCIntermittent pneumatic compression; inflatable sleeves that sequentially inflate/deflate to compress limbs

HPIPC / HPILC / high-pressureHigh-pressure, rapid inflation/deflation cycle devices often proposed for arterial insufficiency/PAD

PCDPneumatic compression device; may include advanced/lymphatic specific systems.

Revision History

04/01/2026template_update

Template update: Removed content/language pertaining to the state of Louisiana (administrative/template change; no clinical policy statement changes indicated).

11/01/2025coding_updateLatest

Coding update: Updated list of applicable HCPCS codes to reflect quarterly edits; added E0658 and E0659.

11/01/2025archived

Administrative: Archived previous policy version CS097.R.